EGFR and glioblastoma: Six of the 290 profiled tumors harbored gain-of-function mutations in BRAF (5 p.V600E, 1 p.G596D) while 77 had gain-of-function mutations in EGFR. Consistent with our in-house dataset, primary GBM patients with BRAF-mutated tumors survived somewhat longer than patients with EGFR-mutated tumors (Fig. 3B; mean, 27.68 ± 26.95 and 14.19 ± 11.28 months, respectively; log-rank p-value = 0.09).